According to a document filed with the U.S. Securities and Exchange Commission (SEC), if the transaction between Crinetics Pharmaceuticals Inc. and Vertex Pharmaceuticals is terminated under certain circumstances, the former may be required to pay the latter a termination fee of up to $350.47 million.

The document clarifies the specific circumstances that would trigger this substantial financial obligation. The terms of the agreement show that payment of this fee does not take effect automatically and is closely tied to specific termination conditions. This provides market participants and investors with key details about the financial arrangements behind this potential collaboration.Analysts point out that termination fee clauses of such a large amount are typically intended to safeguard the significant interests of both parties, especially in major strategic partnerships or acquisition negotiations. They not only demonstrate the seriousness and depth of commitment to the deal, but may also reflect the high value and expectations both sides place on its ultimate completion. However, this also means that if the agreement falls through under the stipulated conditions, Crinetics Pharmaceuticals would face significant financial outlays.Currently, the market is closely watching the latest developments from both companies and the specific progress of the deal. The disclosure of such financial arrangement details helps investors more comprehensively assess the risks and potential impacts of the related transaction.